The p73 gene is a candidate tumor suppressor gene that has significant homology to p53. Thus far, p73 has not been investigated in hematopoietic malignancies. We used single-strand conformation polymorphism analysis to examine 60 de novo acute myelogenous leukemia (AML) patients for p73 mutations in exons 4, 6 and 7, which are homologous to the most frequently mutated exons in p53. Mutations were not found, but we did identify polymorphisms in exons 4 and 7. We also examined p73 RNA expression in 15 AML samples, eight cell lines, and eight normal bone marrows using the reverse transcriptase/polymerase chain reaction assay. All 31 RNA samples had p73 expression. Fourteen RNA samples were informative for allelic expression, being heterozygous for a polymorphism in codon 173 of exon 4. The two normal bone marrows and the K562 cell line had evidence of biallelic expression while six of 10 AML patients and the Kasumi (AML) cell line had monoallelic expression. These data suggest that functional p73 mutations in exons 4, 6 and 7 do not occur in most de novo AML patients. In addition, biallelic expression of p73 occurs in normal bone marrows, some AML samples, and specific cell lines. Lastly, monoallelic p73 expression appears to be common in de novo AML.
Introduction
Acute myelogenous leukemia (AML) is a heterogeneous disease without a unifying genetic lesion. Common genetic abnormalities in AML include point mutations of the ras oncogene family occurring in 15% of de novo AML patients and cytogenetic changes involving t (15;17) , inv (16) and t (8;21) , each occurring in 5-12% of AML cases. [1] [2] [3] [4] [5] Like many malignancies, AML seems to escape the normal regulatory processes of the cell cycle and to evade apoptosis by tumor suppressor genes. The p53 tumor suppressor gene plays a vital role in normal G1/S checkpoint control and programmed apoptosis. [6] [7] [8] [9] [10] [11] p53 abnormalities generally involve a loss of heterozygosity (LOH) and a point mutation in the remaining allele. These point mutations are usually localized to 'hot spots' within the DNA binding domain, exons 5,6,7 and 8. 10, 11 Curiously, while alterations of p53 occur in up to 50% of tumors, p53 point mutations are found in only 5% of de novo AML cases. As with other neoplasms, p53 mutations in AML samples primarily occur within the DNA binding domain and especially around codons 175 and 273 ( Figure 1 ). [12] [13] [14] [15] [16] [17] Why are p53 alterations so uncommon in de novo AML? Apoptosis resistance has been documented in a high percentage of AML cases, but the apoptosis resistance does not consistently correlate with either p53 mutations or BCL-2 expression, implying that other tumor suppressor genes may be important in the regulation of apoptosis in AML.
gene candidate on chromosome 1, the p73 gene. Several studies suggest that p73 is a tumor suppressor gene. The p73 gene localizes to the 1p36 locus, and multiple tumors including neuroblastoma, breast cancer, and melanoma contain genetic aberrations involving this locus. [20] [21] [22] In addition, the p73 gene has extensive structural homology to the most conserved regions of p53, with 63% identity to the p53 DNA binding domain ( Figure 1) . 19, 23 Also, p73 and p53 have similar functional qualities. Like p53, the p73 protein localizes to the nucleus, and p73 induces transcription of the p21 cipl cyclindependent kinase inhibitor. In neuroblastoma cell lines without p73 expression, p73 gene transfection suppresses colony growth, 19 and p73 overproduction induces apoptosis. 24 Unlike p53, initial research indicated that p73 was imprinted. 19, 25 Imprinting would reduce the functional p73 alleles to a single allele similar to LOH. Thus, a single mutation in the expressed p73 allele could have important functional significance.
The low frequency of p53 mutations in AML, the homology between p73 and p53, and the imprinting of p73 make the p73 gene an attractive candidate for investigation in AML. We, therefore, evaluated 60 patients with de novo AML for p73 mutations in exons 4, 6 and 7, homologous to p53 'hot spots' and examined p73 allelic expression in AML samples, cell lines, and normal bone marrows.
Materials and methods

Patients and samples
DNA samples were obtained from de novo AML patients ages 17-64 who were enrolled in the Southwest Oncology Group (SWOG) AML Protocol 8600. All diagnostic samples were from either bone marrow or peripheral blood prior to any treatment. Samples underwent Ficoll gradient separation and DNA extraction as previously described. 1 Control DNA samples were obtained from normal bone marrows. RNA samples were extracted from diagnostic AML samples or normal bone marrows using the phenol/chloroform method (TRIzol; Gibco BRL, Grand Island, NY, USA). A comparison of the genomic structure of p53 and p73. T/C and C/T denote the polymorphisms in exons 4 and 7, respectively. Primers for p73 are shown with their respective exons. R175, G245, R248, R249, R273, and R282 are codon 'hot spots' in the p53 DNA binding domain that are frequently mutated.
Polymerase chain reaction (PCR
CA, USA). Tubes were kept on ice until the PCR began. 25 l of the amplification mixture was loaded into positive displacement syringe tips (Tri-continent Scientific, Grass Valley, CA, USA), and the tips were heat-sealed using Corbett Automatic Capillary Sealer (Corbett Research, Mortlake, NSW, Australia). Each PCR reaction was performed on FTS-1S Capillary Fast Thermal Sequencer (Corbett Research). The first PCR cycle consisted of denaturing at 95°C for 5 min, annealing at 65°C for 60 s, and extending at 72°C for 10 s. The next four cycles were denaturing at 95°C for 15 s, annealing at 65°C for 45 s, and extending at 72°C for 15 s. These cycles were followed by 45 cycles of denaturing at 95°C for 5 s, annealing at 65°C for 20 s, and extending at 72°C for 10 s. A final extension step at 72°C for 2 min was performed. The primers for p73 were as follows: exon 4 → 5ЈCCG CTC TTG AAG AAA CTC TAC 3Ј and 5Ј TTG AAG TCC CTC CCG AGC TCG 3Ј; exon 5→ 5Ј ACA GTC TGC TCC AGC CAG CC 3Ј and 5Ј TGG CTC ATA GGG CAC CAC GAC G 3Ј; exon 6→ 5Ј GTG GGG ACG GAA TTC ACC ACC 3Ј and 5Ј ATC CCG CAT CTC CAG GGT GAT 3Ј; and exon 7 → 5Ј GGG CAG GTG CTG GGC CGC CGG 3Ј and 5Ј CTT GCT GGC GGC CCC GTT CTT 3Ј.
Reverse transcriptase reaction and PCR (RT/PCR) of RNA for p73 expression
RT/PCR was used to amplify exons 4, 5,6 and 7. RT and PCR were performed as two separate reactions. The RT reaction contained 200 U SuperScript II H Reverse Transcriptase (Gibco BRL), 0.08 mM DTT (Gibco BRL), 4 l 5× first strand buffer (Gibco BRL), 0.4 pM poly T, 0.4 mM deoxynucleotides, 500 ng RNA, 0.125 l RNAse inhibitor (5 Prime → 3 Prime, Boulder, CO, USA), and DEPC to a total of 20 l. The RT step was performed at 42°C for 50 min followed by inactivation step of 70°C for 15 minutes. The PCR amplification of cDNA included 2 l of cDNA, 0.2 pM of appropriate primers, 2.5 l of 10× PCR amplification buffer, 0.5 mM of MgCl 2 , 0.2 mM of deoxynucleotides, standardized amounts of Ampli Taq Polymerase plus Taq Start Antibody, and DI water to a total of 25 l. The PCR amplification of cDNA was performed in the thin capillary tube system. The initial cycle consisted of denaturing at 95°C for 5 min, annealing at 60°C for 60 s, and extending at 72°C for 60 s. The next four cycles featured denaturing at 95°C for 30 s, annealing at 60°C for 45 s, and extending at 72°C for 30 s. The next 40 cycles consisted of denaturing at 95°C for 15 s, annealing at 60°C for 30 s, and extending at 72°C for 20 s. After 45 cycles, a final extension step at 72°C for 5 min was added. RT/PCR of ␤ 2 -microglobulin was used as a control for RNA integrity as previously described. 27 
Single-strand conformation polymorphisms (SSCP)
SSCP analysis was performed to detect mutations in the PCRamplified exons. 28 5 l of the PCR product was added to 3 l of 100% formamide, 2 l of running dye, and 8 l of 1% TBE. The mixture was heated to 95°C for 10 min, and then placed on ice. The denatured PCR product was electrophoresed through pre-cast 20% TBE (Novex, San Diego, CA, USA) in the XCell II Mini-Cell gel electrophoresis unit (Novex) in 1% TBE buffer. 29 The temperature was uniformly maintained by a ThermoFlow ETC Unit (Novex) and an Isotemp 1016S Circulator (Fisher Scientific, Pittsburgh, PA, USA). We initially performed SSCP at multiple temperatures to optimize the best separation of single-stranded DNA. The SSCP patterns at 15°C and 25°C had the best banding resolution for exons 4 and 6, and 25°C was optimal for exon 7. All gels were stained with SYBR Green II RNA Stain (Molecular Probes, Eugene, OR, USA) 45 min without prewashing or destaining. Gels were examined for ssDNA shifts on an Eagle Eye II optical system (Stratagen, Coolsville, CA, USA).
Direct nucleotide sequencing of the amplified fragments
SSCP bands were cut from pre-cast 20% TBE SSCP gels and incubated overnight at 4°C in 100 l of 5 M NH 4 OAc. DNA was then precipitated with 350 l of cold EtoH 100%. The solution was spun at relative centrifugal field (RCF) 12 400 for 5 min (Beckman Microfuge 12, Toronto, Canada), and the supernatant removed. The pellet was washed with 100 l of cold EtoH 75%, respun at the same RCF, and supernatant removed. The DNA was dried and resuspended in 20 l of DI water. The resuspended DNA was reamplified by PCR to generate sequencing template. PCR products were run on a 2% agarose/1× TAE gels with ethidium bromide, and appropriate bands cut out. The product was extracted with 100 l of DI water filtered through Spin-X Centrifuge tube (Corning Costar, Oneonta, NY, USA) by centrifuging at RCF 12 400 for 5 min. This step was repeated a total of three times. DNA was precipitated with 40 l of 5 M NH 4 OAc and 800 l of 100% EtoH, spun at RCF 12 400, and supernatant removed. The pellet was washed with 75% EtoH as previously described, dried, and resuspended with 20 l DI water. The direct fluorescence sequencing reaction was performed using a Thermo Sequence Dye Terminator Premix (Amersham). Approximately 10 pM of gel purified, reamplified product was added to 8 l of premix, 10 pM of either 5Ј or 3Ј primer, and enough DI water to bring the solution to 20 l. The dye terminator sequence reaction was 25 cycles at the following conditions: 96°C for 10 s, 50°C for 5 s, and 60°C for 4 min. The DNA sequence was read with Applied Biosystems 373XL DNA Sequencer (Perkin-Elmer, Foster City, CA, USA) using 5% Long Ranger Acrylamide gel.
Results
Mutations in p73 exons 4, 6 and 7
We screened the DNA of 60 de novo AML patients and 12 normals for p73 mutations. We examined exons 4, 6 and 7 of p73 because of their homology to p53 exons with codon 'hot spots' (Figure 1) . 19 All samples had excellent p73 amplification (data not shown), and sequencing confirmed that the amplified products were the appropriate exons. Exon 7 from patient No. 53 had a shifted band by SSCP, and the DNA sequence revealed a base pair substitution (TCC → TCT) in codon 319 of exon 7 (data not shown). This C → T substitution does not change the amino acid (Serine), and thus is thought to be 'silent.' We also found a more frequent 'silent' polymorphism (ACT → ACC, Threonine) in codon 173 of exon 4 (data not shown). The heterozygous polymorphism (T/C) in exon 4 was present in 12 of 60 (20%) de novo AML samples and two of 12 (16%) normal marrows. A homozygous (C/C) base substitution in codon 173 was found in one of 60 de novo AML samples and one of 12 normal marrows. For each exon, we also sequenced nine samples without abnormally shifted bands. All samples without abnormally shifted bands had wild-type sequences (data not shown).
p73 expression
We used RT/PCR to examine p73 expression in 15 AML patients, eight normal controls, and eight cell lines. All samples had ␤ 2 -microglobulin amplification. Primers, 4.5/5.3 and 6.5/7.3, were used for the expression assays since intervening introns would distinguish RNA from any DNA amplification (Figure 1 ). RT/PCR amplified a 290 bp product using the 4.5/5.3 primers and a 250 bp product using the 6.5/7.3 primers (data not shown). Sequencing of the RT/PCR products confirmed the appropriate exons without intron sequences. The 15 AML samples, eight normal bone marrows, and eight cell lines had clear expression of p73. The eight cell lines were TC 71 (Ewings), TTC 466 (Ewings), RD (rhabdomyosarcoma), RH 30 (rhabdomyosarcoma), HB (ALL), Kasumi (AML), K562 (erythroleukemia), and HL60 (AML). Of interest, HL60 had previously been reported not to have p73 expression. 19 
Allelic expression of p73
Fourteen samples were heterozygous for the exon 4 polymorphism (T/C), and we used the 4.5/5.3 primers to examine allelic expression in these informative samples. The two normal bone marrows, the K562 cell line, and four of 10 AML samples had biallelic expression (Figure 2a) while six of 10 AML samples and the Kasumi cell line had preferential expression of one allele (Figure 2b ). To verify biallelic expression, we reamplified DNAse-treated RNA using RT/PCR. A repeat SSCP analysis of the RT/PCR products confirmed biallelic expression in the two normal bone marrows and the K562 cell line. The Kasumi cell line again demonstrated preferential expression of the C allele (Figure 2c ).
Discussion
We used PCR/SSCP analysis to examine 60 de novo AML samples for p73 mutations in exons 4,6 and 7, areas homologous to p53 'hot spots' (Figure 1 ). p73 coding mutations were not found in the 60 de novo AML samples tested, but we identified polymorphisms in 14 of 60 AML samples and three of 12 normal samples. Sixteen of these polymorphisms were in codon 173 of exon 4. In addition, we used RT/PCR to evaluate p73 expression in 15 AML patients, eight cell lines, and eight normal bone marrows. All 31 RNA samples demonstrated p73 expression. Fourteen RNA samples were informative with a heterozygous (T/C) polymorphism in codon 173. Biallelic expression was found in the normal bone marrows, the K562 cell line, and some AML samples. Interestingly, the 60% of the informative AML samples and the Kasumi cell line had monoallelic expression.
Although a variety of genetic lesions have been described in AML, a predominant genetic abnormality has not been identified. [2] [3] [4] [5] 30, 31 Many malignancies avert apoptosis, and p53 mutations appear to be a common mechanism to escape the GI/S 'checkpoint.' We wondered if p53 mutations in AML are rare because another p53 family member, such as p73, is mutated. To date, coding p73 mutations have not been found in any solid tumors including lung, prostate, colon, or oligodendrogliomas. 25, [32] [33] [34] [35] We also did not find any p73 mutations in the areas analogous to mutational 'hot spots' in p53, but we cannot exclude that p73 mutations may occur outside these exons or in specific intron regions important in gene regulation. 36, 37 Moreover, point mutations in p73 may not be the only way to abrogate or compromise p73 function. For example, p53 structure and function can be altered by conformational changes in the p53 protein, splicing abnormalities, viral protein binding, and upregulation of intrinsic proteins such as MDM-2. 6, 8, 17, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Thus, the absence of p73 coding mutations does not exclude p73 from playing a role in AML.
p73 seems to be expressed in a variety of different tissues, 25, [32] [33] [34] [35] and p73 was universally expressed in de novo AML samples, cell lines, and normal bone marrows. The data regarding p73 allelic expression remain controversial. Two studies suggest that the gene has monoallelic expression in normal tissue while another study seems to contradict this observation. 19, 25, 32 The later study demonstrated biallelic expression in 25 of 26 'normal' lung samples from patients with lung cancer. Interestingly, intertissue allelic expression differences were found in one patient at necropsy, indicating that allelic expression patterns may be tissue dependent. 32 To date, only one published study has examined p73 expression in the blood, and all five normal individuals had monoallelic expression. 19 All three studies used polymorphisms at positions 4 and 14 of the noncoding exon 2, upstream from the first AUG. 19, 25, 32 There are several explanations for these conflicting results.
(1) The exon 2 polymorphisms are thought to form a stem-loop, 19 and this could selectively disrupt the RT/PCR of one of the alleles. (2) Exon 2 could be preferentially spliced from the RNA of one allele giving the impression of monoallelic expression. Two splicing variants involving exon 13 have already been described for p73. 19 (3) Intertissue expression differences could explain the results. If a specific tissue type preferentially expressed only one allele, monoallelic or biallelic expression would merely reflect the amount of heterogeneity of tissue types in the sample.
We found a total of 14 informative samples that were heterozygous (T/C) in codon 173 of exon 4, a coding region of p73. Fifty percent of the informative samples expressed both alleles. Interestingly, both the informative normal bone marrows had biallelic expression, but one must be cautious interpreting the allelic expression patterns of p73 in normal bone marrow since random or nonrandom monoallelic expression in different cell types would give the appearance of biallelic expression. We also found biallelic expression in K562 and 40% of AML samples. The K562 represents a fairly homogenous population of cells, and all the diagnostic AML samples had over 50% blasts, with the average bone marrow having greater than 78% blasts. Thus, these results suggest that both alleles can be expressed in hematopoietic cells.
Conversely, 60% of the AML samples and the Kasumi cell line preferentially expressed one allele. Several studies have demonstrated that other malignancies have only one functioning p73 allele. 19, 32, 35 Nomoto et al 32 found frequent p73 LOH (42%) in lung cancer samples, and p73 LOH has also been reported in prostate cancer. 35 How does one explain the variable allelic expression of one p73 allele in AML? We are currently investigating possible explanations. One hypothesis is that aberrant methylation prevents expression of p73 in AML. Aberrant methylation has been described in both AML and CML, 51, 52 and abnormal methylation has been shown to affect the regulation of specific genes in AML. 53, 54 Aberrant methylation could cause dysregulation of numerous genes including p73, and this global dysregulation may contribute to transformation. The significance of monoallelic expression of p73 in AML remains to be defined, but recent studies have demonstrated that tumor suppressor gene dysfunction can be caused by a relative decrease in expression levels, rather than total loss of function. The loss of one p27
Kip1 allele in knockout mice decreases p27
Kip1 protein production and increases tumorigenesis. 55 By analogy, the monoallelic expression of p73 may be sufficient to disrupt the normal activity of the gene.
In conclusion, our results suggest that: (1) p73 mutations in exons 4, 6 and 7 are rare and may not occur in AML; (2) polymorphisms in exon 4 are frequent, occurring in about 20% of normal and malignant samples; (3) p73 expression is not strictly monoallelic; and (4) monoallelic expression of p73 is common in de novo AML. Further studies are necessary to determine the role of p73 expression and function in cell regulation, apoptosis, and leukemogenesis.
